About
Paige.AI is a leader in computational pathology, leveraging next-generation AI foundation models to address cancer's most critical diagnostic challenges. Founded by pathology and AI experts, Paige was among the first organizations to apply large-scale foundation models—trained on over 1.5 million slides—to clinical cancer care. Their flagship product, Paige Alba™, is a multi-modal AI co-pilot designed to revolutionize pathology workflows and unlock precision medicine. Their diagnostic AI suites include the Paige Prostate Suite, Paige Breast Suite, Paige GI Suite, and Paige PanCancer Suite—each built to assist pathologists in detecting and classifying cancerous conditions on H&E-stained whole-slide images with unprecedented accuracy. Beyond diagnostics, Paige offers a robust AI Technology & Services platform. Their proprietary foundation models—Virchow, Virchow2, Virchow2G, and PRISM—can be licensed by life sciences organizations to accelerate computational pathology R&D, build custom AI models, identify novel biomarkers, and optimize clinical trial design without requiring task-specific training. Additionally, their OmniScreen solutions provide AI-driven prescreening and characterization capabilities for large-scale cancer screening programs. Paige is purpose-built for enterprise healthcare and life sciences organizations, helping pathologists manage growing workloads while delivering high-quality, AI-informed diagnoses.
Key Features
- Paige Alba™ Multi-Modal Co-Pilot: A proprietary AI co-pilot designed to revolutionize pathology workflows by integrating multi-modal data to support precision medicine and clinical decision-making.
- Diagnostic AI Suites: Specialized AI application suites for prostate, breast, GI, and pan-cancer diagnostics that detect and classify conditions on H&E-stained whole-slide images.
- Virchow Foundation Models: A family of large-scale pathology foundation models (Virchow, Virchow2, Virchow2G, PRISM) trained on over 1.5 million slides, available for licensing to accelerate R&D.
- OmniScreen AI Prescreening: AI-driven large-scale cancer prescreening and characterization solutions to identify at-risk patients and prioritize diagnostic workloads.
- Molecular Biomarker Discovery: Novel AI technologies that reveal multiple molecular biomarkers directly from tissue samples, enabling targeted therapies and clinical trial optimization.
Use Cases
- Assisting pathologists in detecting and grading prostate cancer on needle biopsy whole-slide images to reduce diagnostic errors and workload.
- Supporting breast cancer classification and subtyping from biopsy and excision specimens to enable faster, more accurate treatment planning.
- Screening large patient populations for GI cancers using OmniScreen AI to prioritize high-risk cases for immediate review.
- Enabling life sciences companies to license foundation models for developing custom computational pathology AI applications and clinical trials.
- Discovering molecular biomarkers directly from tissue samples to identify therapeutic targets and advance precision oncology research.
Pros
- Pioneering Foundation Model Approach: Among the first to apply large-scale foundation models to pathology, trained on 1.5M+ slides, delivering state-of-the-art performance across cancer types.
- Comprehensive Cancer Coverage: Broad diagnostic AI suites covering prostate, breast, GI, and pan-cancer conditions, making it a one-stop platform for oncology pathology.
- Licensable Technology for R&D: Life sciences companies can license Paige's foundation models and AI modules to build custom applications without costly task-specific training.
- Clinically Validated: Backed by extensive clinical evidence including peer-reviewed publications and posters, providing confidence in real-world diagnostic settings.
Cons
- Enterprise-Only Pricing: Paige.AI is designed for enterprise healthcare and life sciences organizations; pricing is not publicly available and likely out of reach for smaller labs or individual practitioners.
- Narrow Vertical Focus: The platform is exclusively focused on oncology pathology, limiting its applicability outside of cancer diagnostics and research.
- Requires Trial Request: Access to the platform requires contacting Paige for a trial, with no self-serve or instant access option available.
Frequently Asked Questions
What is Paige.AI?
Paige.AI is a clinical AI company specializing in computational pathology. It provides AI-powered diagnostic tools and foundation models to assist pathologists in detecting and classifying cancer from tissue slide images.
What types of cancer does Paige.AI support?
Paige.AI offers diagnostic AI suites for prostate, breast, gastrointestinal (GI), and pan-cancer types, covering a wide range of oncology diagnostic needs.
What are the Virchow foundation models?
Virchow is a family of pathology-specific foundation models (Virchow, Virchow2, Virchow2G, Virchow2G-Mini, PRISM) trained on over 1.5 million slides. They can be licensed by life sciences organizations to build custom computational pathology applications.
What is Paige Alba™?
Paige Alba™ is Paige's proprietary multi-modal AI co-pilot designed to streamline pathology workflows, integrate diverse data sources, and support precision medicine decision-making.
How can life sciences companies use Paige's technology?
Life sciences organizations can license Paige's foundation models and pre-built PanCancer AI modules to accelerate R&D, discover novel biomarkers, optimize clinical trial design, and build custom AI applications without starting from scratch.
